As technology becomes more integrated and personalized, experts say the biggest opportunity in diabetes management is ...
Managing type 2 diabetes can be challenging, especially when it comes to finding the right insulin dose. A new study suggests ...
Your early life may quietly set the stage for developing Type 1 diabetes, an increasingly common, lifelong condition that can ...
Real-world data suggested the dual GLP-1/GIP receptor agonist tirzepatide (Mounjaro, Zepbound) was associated with greater ...
IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial ...
The 19th on MSN
Peptides do a lot. Do you need them?
Peptides — whether insulin or GLP-1's or copper peptides — amplify the work your body is already doing. But they aren't the ...
A team at Stanford Medicine has now identified a naturally occurring molecule that suppresses appetite and promotes fat loss ...
Beta Bionics (Nasdaq:BBNX) today reported first-quarter sales results that came in ahead of the forecast on Wall Street.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results